-
Contributors
-
Author Archives: Barbara Arzymanow
The Health and Social Care Bill: Final Stages in Parliament
With opposition to the Health and Social Care Bill having reached new heights, we must look behind the rhetoric and remember basic principles. The most important point to remember is that the NHS exists to provide the best possible, affordable … Continue reading
Posted in NHS, Hospitals, competition, David Cameron, Inequality, Department of Health, Andrew Lansley, GPs, Business, Health Bill, Patients, Commissioning, Patient choice
Tagged health, NHS, 2020health, Department of Health, Responsibility in healthcare, competition, David Cameron, government, GP, patient, GPs, NICE, BMA, Commissioning, Old age, National Health Service, Health Bill, Patients, efficiency, Andrew Lansley, Bevan, Nye Bevan, inaccurate media, bureaucracy
Leave a comment
Guest Blogspot: Misleading, Biased Reporting on the Health and Social Care Bill in the Media
Above all the freedom of the Press is paramount. Censorship or severely restrictive legislation is not an acceptable alternative. We sometimes have to accept the consequences and tolerate a Press that can be wrong, unfair, misleading or more interested in … Continue reading
Posted in Andrew Lansley, competition, David Cameron, Department of Health, equality, Finance, Health Bill, Hospitals, Inequality, NHS, Patients, Private
Tagged 2020health, Andrew Burnham, Andrew lansley, Andy Burnham, BBC, Biased reporting, competition, David Cameron, Department of Health, Freedom of the Press, government, Health Bill, hospital beds, journalists, Labour Party, Misleading reporting, National Health Service, NHS, non-NHS income, non-NHS work, patient, Patients, Press, private income cap, private patients, Shirley Williams, theatre time, waiting times
3 Comments
Political Mood Change over the NHS, Innovation and the Pharmaceutical Industry in 2011
As 2011 draws to a close now is a good time to reflect on the period since the last UK General Election in 2010. We must consider what we have done right, what we have done wrong and what remains … Continue reading
Posted in Business, David Cameron, Department of Health, Drugs, Election, Genetics, Health Bill, Health Team, Hospitals, Innovation, NHS, Pharma, Policy, Research
Tagged 2020health, David Cameron, Department of Health, Drugs, genetics, government, GPs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, Pfizer, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
Leave a comment
Parallel importing and exporting of pharmaceuticals severely limits the options in designing an effective UK drug pricing scheme.
A fundamental principle of the EU is the establishment of a single market where products can be freely imported and exported between member states. In the case of pharmaceuticals this ideal conflicts with the freedom of individual countries to fix … Continue reading
Posted in Business, competition, Department of Health, Drugs, Innovation, NHS, Pharma, Policy, Research
Tagged 2020health, competition, Department of Health, Drugs, German pricing, innovation, Lilly, medicine, National Health Service, NHS, NICE, Novartis, parallel exporting, parallel importing, parallel trade, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
1 Comment
Guest Blogspot: The highest standards of medical care urgently require doctors to remain up to date through Continuing Professional Development.
This week the UK regulator of doctors, the General Medical Council (GMC), has launched a consultation over the Continuing Professional Development (CPD) of qualified, practising doctors. This subject is of immense importance because the pace of medical advances is such … Continue reading
Posted in Department of Health, Drugs, Emerging technologies, GPs, Innovation, NHS, Patients, Pharma, Policy, Preventative healthcare, Primary Care, Quality and Safety, Research, Technology, Work
Tagged 2020health, annual appraisal, BMA, Continuing Professional Development, CPD, Department of Health, Drugs, General Medical Council, General practitioner, GMC, GP, GPs, health, innovation, medicine, National Health Service, NHS, NICE, patient, Patients, pharmaceutical, Quality, R&D, Research, Responsibility in healthcare, revalidation, work
4 Comments
Guest Blogspot: What should we expect from medical and pharmaceutical R&D in the future?
Charities representing patients with different illnesses compete to make the case for research and the availability of the best treatment and care in their areas of interest. The autumn party political conferences probably represent the peak campaigning period. Many medical … Continue reading
Posted in Business, Department of Health, Drugs, Emerging technologies, Hospitals, Innovation, mental health, NHS, Patients, Pharma, Policy, Research, Technology
Tagged 2020health, cancer, charities, Department of Health, Drugs, innovation, lupus, medicine, mental health, mergers, National Health Service, NHS, NICE, pharmaceutical, pricing, R&D, Research, think tank, value-based, value-based pricing
Leave a comment
Is it possible for NICE to be objective about pharmaceutical pricing?
Guest Blog: Barbara Arzymanow The Government appears to recognise the past shortcomings of NICE (National Institute for Health and Clinical Excellence) but no other organisation in the UK is appropriate to make expert recommendations on the value of individual drugs. … Continue reading
Posted in Andrew Lansley, Department of Health, Drugs, NHS, Pharma, Research
Tagged 2020health, Andrew lansley, Department of Health, Drugs, National Health Service, NHS, NICE, patient, pharmaceutical, PPRS, pricing, value-based pricing
Leave a comment
Guest Blogspot – The UK Government’s Latest Thinking on the Value-Based Pricing of Medicines
The UK Government yesterday published its detailed response to the three-month public consultation concluded in March 2011 on value-based pharmaceutical pricing. The Government has emphasised that work on the proposals is still at an early stage. The mistake made with … Continue reading
Posted in Andrew Lansley, Business, Department of Health, Drugs, Employment, Finance, Innovation, NHS, Patients, Pharma, Policy, Research
Tagged 2020health, Alzheimer's Disease, Andrew Dillon, Andrew lansley, Department of Health, Drugs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, patient, patient access, Patients, Pfizer, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
Leave a comment
Guest Blogspot: NHS Reforms- What the UK Government Policy Changes Really Mean
There is a strong consensus amongst independent experts, medical professionals and politicians that major NHS reforms are both desirable and inevitable. Healthcare is one of mankind’s greatest priorities. An aging population and medical advances mean that healthcare expenditure is bound … Continue reading
Posted in Andrew Lansley, Business, competition, David Cameron, Department of Health, Drugs, Elderly, GPs, Health Bill, Hospitals, NHS, Policy, Research, White Paper
Tagged 2020health, Andrew lansley, cherry picking, Commissioning, competition, David Cameron, Department of Health, elderly, GP, GPs, health, Health and Social Care Bill, Health Bill, Ipsos MORI, National Health Service, NHS, NHS Reforms, Patients, pricing, Quality, R&D, Research
Leave a comment
Guest Blogspot – The UK Needs More Biotechnology Companies
The success of US biotechnology companies contrasts sharply with the disappointment in other countries. British companies valued by stock markets at more than about US $ 4 billion go in the FTSE 100 index. There are no biotechnology companies big … Continue reading
Posted in Business, Drugs, Emerging technologies, Finance, Genetics, Pharma, Policy, Research, Technology
Tagged 2020health, Amgen, biotechnology, biotechnology company, block-buster, blockbuster, BTG, drug pricing, Genentech, genetics, medicine, Nobel Prize, patent box, pharmaceutical, pricing, R&D, R&D tax credit, Research, value-based, value-based pricing
Leave a comment
